Rhythm Pharmaceuticals Inc (RYTM)

Apr 7, 2025, 7:11 AM EDT - 19 hours ago

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Apr 7, 2025, 7:00 AM EDT - 19 hours ago

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Apr 6, 2025, 12:00 PM EDT - 1 day ago

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Mar 31, 2025, 2:05 PM EDT - 7 days ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI ALNY VRTX XENE

Mar 20, 2025, 4:01 PM EDT - 18 days ago

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Mar 19, 2025, 4:01 PM EDT - 19 days ago

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Mar 18, 2025, 7:00 AM EDT - 20 days ago

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Feb 26, 2025, 1:46 PM EST - 5 weeks ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 5 weeks ago

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 25, 2025, 11:21 AM EST - 5 weeks ago

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 13, 2025, 8:00 AM EST - 7 weeks ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Jan 10, 2025, 7:15 AM EST - 3 months ago

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Dec 20, 2024, 2:24 PM EST - 3 months ago

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Dec 20, 2024, 2:15 PM EST - 3 months ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Dec 3, 2024, 6:00 AM EST - 4 months ago

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Nov 18, 2024, 7:00 AM EST - 5 months ago

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Nov 13, 2024, 6:30 PM EST - 5 months ago

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Nov 13, 2024, 4:01 PM EST - 5 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Nov 6, 2024, 8:00 AM EST - 5 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Nov 5, 2024, 10:45 PM EST - 5 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 4:01 PM EST - 5 months ago

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

Nov 4, 2024, 4:01 PM EST - 5 months ago

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

Oct 24, 2024, 6:00 AM EDT - 5 months ago

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

Sep 22, 2024, 7:36 AM EDT - 7 months ago

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Aug 29, 2024, 9:30 AM EDT - 7 months ago

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 26, 2024, 8:02 AM EDT - 8 months ago

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

Aug 19, 2024, 1:49 PM EDT - 8 months ago

Three Biotech Stocks to Buy for the "Golden Age of Medicine"

LLY SNY

Aug 6, 2024, 11:22 AM EDT - 8 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 8 months ago

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

Jul 31, 2024, 9:10 AM EDT - 8 months ago

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Jul 23, 2024, 7:30 AM EDT - 9 months ago

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Jun 28, 2024, 8:00 AM EDT - 10 months ago

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

Jun 3, 2024, 4:02 PM EDT - 11 months ago

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

Jun 3, 2024, 8:02 AM EDT - 11 months ago

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

May 22, 2024, 4:00 AM EDT - 11 months ago

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

May 7, 2024, 9:50 PM EDT - 11 months ago

Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Earnings Call Transcript

May 7, 2024, 7:00 AM EDT - 11 months ago

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

Apr 29, 2024, 6:30 PM EDT - 1 year ago

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

Mar 28, 2024, 9:33 AM EDT - 1 year ago

Hennion & Walsh's Kevin Mahn on his top stock picks: CRWD, MSFT, LLY, RYTM

LLY MSFT CRWD

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Mar 6, 2024, 4:01 PM EST - 1 year ago

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Feb 22, 2024, 11:33 PM EST - 1 year ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 7:01 AM EST - 1 year ago

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Feb 22, 2024, 7:00 AM EST - 1 year ago

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

Jan 31, 2024, 8:00 AM EST - 1 year ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

Jan 4, 2024, 7:00 AM EST - 1 year ago

Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640

Jan 4, 2024, 6:58 AM EST - 1 year ago

Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

Dec 13, 2023, 7:00 AM EST - 1 year ago

Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023